U.S. Healthtech Stock News

Earlier this month, Oklo Inc. filed to raise up to US$1.50 billion through an at-the-market Class A common stock offering to fund its pre-revenue advanced nuclear reactor program and broader corporate needs. The move underscores how capital-intensive Oklo’s path is, as it works toward licensing compact reactors aimed at powering energy-hungry AI data centers and other long-term customers. We’ll now look at how this large at-the-market equity raise shapes Oklo’s investment narrative around...

Wondering if Digital Realty Trust is actually a bargain at today’s price, or just another pricey data center REIT dressed up in AI hype? Let us unpack what the market is really paying for here. After a recent close around $163.78, the stock is up 4.7% over the last week but still down 3.6% over 30 days and 7.5% year to date, despite a strong 68.1% gain over 3 years and 50.8% over 5 years. Recent price moves have been driven by ongoing enthusiasm for data center and AI infrastructure, with...

Planet Fitness (PLNT) just locked in $750 million of new senior secured notes, a refinancing move designed to tidy up older debt, bolster reserves, and leave room for potential share buybacks. See our latest analysis for Planet Fitness. The refinancing headlines cap a steady stretch for Planet Fitness, with the latest share price at $109.15 and a 90 day share price return of 6.40% alongside a three year total shareholder return of 45.09%, suggesting momentum is gradually rebuilding. If this...

Virco Mfg (VIRC) just turned in a softer Q3 2026, with revenue of about $47.6 million and a basic EPS loss of roughly $0.08, even as its trailing twelve month revenue held at around $201.9 million alongside EPS of about $0.24. Over the past several quarters the company has seen quarterly revenue swing from $108.4 million in Q2 2025 to $92.1 million in Q2 2026 and $47.6 million in the latest quarter, while EPS has moved from a high of $1.04 to $0.65 before slipping into the red. This sets up a...

Signet Jewelers (NYSE:SIG) just delivered a stronger third quarter, lifted its full year outlook, and paired that with an ongoing buyback and steady dividend. This combination naturally sharpens investor attention. See our latest analysis for Signet Jewelers. Those stronger numbers and the raised outlook help explain why the latest 1 day share price return jumped 5.29 percent, even though the 30 day share price return of minus 12.88 percent signals fading near term momentum. At the same time,...

Dolby Laboratories (DLB) just added two fresh touchpoints for its technology, a Dolby Home Experience hub with Nebraska Furniture Mart and a Dolby Atmos deal in Tata Motors new Sierra, giving investors more to watch than the share price. See our latest analysis for Dolby Laboratories. These home and in car wins arrive while the 1 year total shareholder return sits at about negative 14 percent and the year to date share price return is also negative. This suggests that solid underlying revenue...

Sociedad Química y Minera de Chile (NYSE:SQM) just took a breather, slipping after Goldman Sachs cut its rating to Neutral. The firm cited softer lithium price expectations and heavier upcoming capex that could squeeze free cash flow. See our latest analysis for Sociedad Química y Minera de Chile. That downgrade taps the brakes on what had been strong momentum, with a roughly 23.9% 1 month share price return and about 67.8% year to date, even though the 3 year total shareholder return is...

Wondering if Jabil at around $225 is still a smart buy or if the easy money has already been made? This article will walk through whether the current price lines up with its underlying value. The stock has been on a tear, climbing 7.3% over the last week, 57.8% year to date, and 68.2% over the past year, with a 469.9% gain over five years that has clearly reset market expectations. Behind these moves, investors have been reacting to Jabil sharpening its focus on higher margin, design rich...

In recent months, American Express has reinforced its premium focus by successfully raising Platinum Card fees, expanding high-end perks, and delivering record revenue and earnings per share alongside strong cardmember growth, particularly among younger customers. This combination of higher-priced premium offerings, resilient spending by affluent and next-generation users, and company guidance pointing to further revenue and earnings expansion underscores how tightly American Express’s...

In early December 2025, Opera began rolling out new AI capabilities across its Opera One, Opera GX and Opera Neon browsers, integrating Google’s latest Gemini models to deliver faster, context-aware assistance, voice interaction and file analysis to more than 80 million users. An interesting angle is that these AI tools are tightly linked to Opera’s query monetization, potentially deepening how the browser converts user intent into e-commerce and service referrals. Next, we’ll examine how...

Wondering if Leidos Holdings is still a smart buy after its big run, or if the easy money has already been made? This breakdown will help you decide whether the current price still offers value. The stock trades around $185.62 after a modest pullback of 1.5% over the last week and 5.8% over the last month. It is still up 29.5% year to date and 17.0% over the last year, with a 78.8% gain over three years and 89.8% over five years. Recent moves have been shaped by steady contract wins in...

PAR Technology (PAR) has quietly slid over the past year, with the stock now trading more than 50% below its year to date level, even as annual revenue and earnings trends improve. See our latest analysis for PAR Technology. That slide reflects a sharp reset in sentiment, with the share price now at $33.51 after a 90 day share price return of negative 28.49 percent and a one year total shareholder return of negative 56.59 percent. This comes despite a still solid three year total shareholder...

The Centers for Medicare & Medicaid Services recently finalized 2026 rules that significantly increase reimbursement rates for Inspire Medical Systems’ obstructive sleep apnea treatment devices, prompting several analysts to upgrade their views on the company’s prospects. At the same time, Inspire faces securities class action lawsuits alleging it misrepresented demand and launch readiness for its Inspire V system, highlighting a tension between stronger reimbursement support and questions...

Coca-Cola Consolidated (COKE) just lined up a $1.35 billion loan agreement, a sizable financing move that should reshape its debt profile and give management more room to maneuver strategically. See our latest analysis for Coca-Cola Consolidated. The financing news lands after a strong run in the stock, with Coca-Cola Consolidated’s share price at $164.51 and a 30 day share price return of 19.40 percent, backed by a powerful 5 year total shareholder return of 554.40 percent that suggests...

Catalyst Pharmaceuticals (CPRX) just delivered an upside third quarter, as strong Firdapse sales and growing Agamree revenue pushed results ahead of expectations and prompted management to raise its 2025 full year sales guidance. See our latest analysis for Catalyst Pharmaceuticals. That stronger outlook seems to be feeding into sentiment, with the stock showing a 15.8% 90 day share price return and a hefty 5 year total shareholder return above 500%. This suggests momentum is still building...

Earlier this month, Citigroup initiated coverage on Matador Resources with a new Buy rating, joining a field of 21 brokerage firms that collectively rate the company as Outperform. This fresh coverage underscores how Matador’s upstream oil and gas operations are drawing increased institutional attention within the broader energy extraction landscape. We’ll now explore how Citigroup’s new Buy rating may influence Matador’s existing investment narrative built around Delaware Basin...

In the past quarter, Credo Technology Group Holding Ltd reported a jump in revenue to US$268.03 million and moved from a small loss to US$82.64 million in net income, with earnings per share turning positive on both a basic and diluted basis. Alongside these stronger results, Credo issued higher third-quarter fiscal 2026 revenue guidance of US$335 million to US$345 million, signaling management’s confidence in continued demand for its high-speed connectivity solutions. With revenue and...

Johnson & Johnson (JNJ) keeps grinding higher, and with the stock up roughly 14% over the past 3 months and nearly 40% year to date, investors are asking what is driving the momentum. See our latest analysis for Johnson & Johnson. That surge has been backed by a solid 8% 1 month share price return and a powerful near 40% year to date share price gain, while a 5 year total shareholder return of about 56% shows momentum has been building, not fading, for long term holders. If J&J’s run has you...

Earlier this month, RadNet, Inc. filed a new omnibus shelf registration and closed a US$5.85 million shelf takedown covering 73,567 common shares for potential resale by existing stockholders, alongside registration capacity for preferred stock, debt securities, warrants, subscription rights, and units. While this move does not alter RadNet’s operating performance, it signals increased flexibility for existing holders to sell, which can influence how investors think about future share...

Altria Group (MO) has quietly ground higher this year, up about 11% over the past year and roughly flat over the past month, as investors reassess its income and value appeal. See our latest analysis for Altria Group. With the share price now around $58.11, Altria’s modest year to date share price gain alongside a solid three and five year total shareholder return suggests steady income driven momentum rather than a fast growth story, as investors stay comfortable with its risk profile. If...

Wondering if Agilent Technologies is quietly becoming good value, or if the market is still pricing in too much optimism? Let us unpack what the current share price really implies, in plain language. The stock has slipped recently, down 5.1% over the last week and 2.9% over the last month, even though it is still up 6.8% year to date and roughly flat over the last year. Recent headlines have focused on Agilent sharpening its focus on high growth areas like diagnostics, life sciences tools,...

Incyte (INCY) has been quietly rewarding patient shareholders, with the stock up about 39% year to date despite a modest pullback over the past month. That mix of recent weakness and longer term strength creates an interesting entry point for investors watching this mid cap biotech name. See our latest analysis for Incyte. That recent 1 month share price return of negative 8.8 percent, including a sharp 1 day drop, looks more like a breather within a broader upswing, given the roughly 39...

If you are wondering whether Chewy is finally attractive at today’s price or still just a story stock that has run ahead of its fundamentals, this breakdown will help you frame the risk and reward in plain English. Chewy’s share price has been choppy, slipping about 0.5% over the last week but still up 2.7% over the past month and 12.1% over the last year, even after a tough 3-year and 5-year stretch with returns of around -23.3% and -58.2% respectively. Recent moves have come as investors...

Recent commentary around Lam Research (LRCX) has zeroed in on its leadership in etch and deposition tools just as 3D DRAM, advanced packaging, and rising wafer fab equipment spending start to inflect higher. See our latest analysis for Lam Research. That optimism has clearly filtered into the market, with Lam’s share price now at $162.8 after a powerful 90 day share price return of 54.21 percent and a three year total shareholder return of 263.15 percent. This indicates strong, still building...